Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
William B WhiteKenneth G SaagMichael A BeckerJeffrey S BorerPhilip B GorelickAndrew WheltonBarbara HuntMajin CastilloLhanoo Gunawardhananull nullPublished in: The New England journal of medicine (2018)
In patients with gout and major cardiovascular coexisting conditions, febuxostat was noninferior to allopurinol with respect to rates of adverse cardiovascular events. All-cause mortality and cardiovascular mortality were higher with febuxostat than with allopurinol. (Funded by Takeda Development Center Americas; CARES ClinicalTrials.gov number, NCT01101035 .).